tapebrief
SOLV · Q4 2025

SOLV · Q1 2026 Earnings

Cautious

Solventum

Reported May 5, 2026

30-second summary

Solventum opened FY2026 with Q1 organic growth of +2.1% (within the +2.0–3.0% FY guide but at the low end) and non-GAAP EPS of $1.48, with management now pointing adjusted EPS to the "high end" of the unchanged $6.40–$6.60 FY range. The new disclosure that matters: $100M+ of sales is being pulled into Q2 ahead of the Q3 U.S./Canada ERP cutover and will reverse mostly in Q3 — creating a near-term optical Q2 beat followed by a Q3 air-pocket that materially complicates segment modeling. Underneath the headline organic print, MedSurg organic was only +1.2% (with AWC +2.1% and IPSS +0.6% against a prior-year IPSS comp "just over 8%"), Dental was +3.4%, and HIS at +4.7% was the only segment to clear the +4% bar — narrowly missing the "above +5%" framing from last quarter. FCF came in at -$273M, the worst first-quarter cash print of the post-spin era.

Headline numbers

EPS

Q1 FY2026

$1.48

Revenue

Q1 FY2026

$2.01B

-3.0% YoY

Gross margin

Q1 FY2026

54.6%

Free cash flow

Q1 FY2026

$-0.27B

Operating margin

Q1 FY2026

4.0%

Key financials

Q1 FY2026
MetricQ1 FY2026YoYQ4 FY2025QoQ
Revenue$2.01B-3.0%$2.00B+0.4%
EPS$1.48—$1.57-5.7%
Gross margin54.6%—51.4%+320bps
Operating margin4.0%—6.2%-220bps
Free cash flow$-0.27B—$0.03B-927.3%

Guidance

Guidance reaffirmed across EPS, free cash flow, and operating margin for FY2026; Q1 organic sales growth of 2.1% met expectations, with new forward guidance disclosing a $100M+ sales timing benefit in Q2 FY2026.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

MetricPeriodPrior guideActualΔResult
Organic Sales GrowthQ1 FY20262.0% to 3.0%2.1%in-lineMet
Organic Sales Growth (excluding SKU exits)Q1 FY20263.0% to 4.0%Approximately 3.2% (implied)in-lineMet

New guidance

MetricPeriodGuideYoY
Adjusted Operating MarginQ1 FY202619.5%—
Sales Timing BenefitQ2 FY2026Over $100 million in Q2 expected to reverse mostly in Q3—
Effective Tax RateFY202619.5% to 20.5%—
Foreign Exchange BenefitFY2026Approximately 100 basis points on sales growth—

Reaffirmed unchanged this quarter: Adjusted EPS ($6.40 to $6.60), Free Cash Flow (~$200M), Operating Margin (21.0% to 21.5%)

Segment KPIs

Q1 FY2026
SegmentQ1 FY2026YoY
MedSurg$1.234B+6.6%
Advanced Wound Care$0.497B+10.9%
Infection Prevention and Surgical Solutions$0.737B+3.9%
Dental Solutions$0.354B+7.9%
Health Information Systems$0.342B+4.1%

Other KPIs

Q1 FY2026
SegmentQ1 FY2026
Organic Sales Growth2.1%
Adjusted Operating Income Margin19.5%
MedSurg Operating Margin13.1%
Dental Solutions Operating Margin24.5%
Health Information Systems Operating Margin38.1%

Management tone

Q2 FY2025 ownership-and-raise → Q3 FY2025 execution-with-divestiture-noise → Q4 FY2025 LRP-acceleration-with-margin-pivot → Q1 FY2026 LRP-inevitability-and-portfolio-firepower.

Last quarter the CEO said the LRP "might land this year, hopefully." This quarter the framing has hardened further: "it's not a question of whether we get to our LRP targets of 4% to 5% organic sales growth. It's a question of when." The progression from "whether we could ever get there" (Q1 FY2025) to "when, not whether" (Q1 FY2026) is a 12-month re-rating of management's own posture — even as the reported organic print this quarter (+2.1%) sits well below the 4–5% LRP bar. The dissonance between current run-rate and forward confidence is the single most important interpretive question on the print: either management has visibility into a step-function inflection driven by the ~20 new product launches, or the LRP-inevitability language is running ahead of evidence.

Portfolio optimization escalated from "perpetual lever" (Q4 FY2025) to "perpetual lever for value creation here at Solventum...we will continually assess our businesses for strategic and financial fit...target-rich environment for additional tuck-in acquisitions." The addition of "target-rich environment" language, paired with "balance sheet that gives us the flexibility to pursue them," is the most aggressive M&A posture management has articulated post-spin. It also reads as a hedge: if organic growth doesn't reach LRP via product launches alone, tuck-in M&A becomes the load-bearing lever.

The Transform for the Future framing shifted again. Q3 FY2025 introduced it as a $500M cost/$500M savings program. Q4 FY2025 positioned it as the answer to doubled tariffs. This quarter management framed it as "additional firepower to offset" headwinds while still expanding margins 50–100bps — and CFO commentary in Q&A clarified that the ERP cutovers are not the savings driver; Transform is. That is a meaningful clarification because it isolates Transform as a standalone margin lever rather than letting it commingle with ERP-cutover benefits in investor models.

The autonomous-coding narrative got its most quantified articulation yet: "80–90% of coding could eventually be autonomous," with a target of "close to 50% of customers" migrating during the strategic plan period. This is the first time management has put adoption-share numbers behind the AI-in-HIS thesis. With HIS organic at +4.7% (acceleration but still short of the +5% bar), quantifying the multi-year glide path lets management defend the segment without anchoring on quarterly prints.

Recurring themes management leaned on this quarter:

Innovation pipeline as growth accelerant (20 new products over 2 years)Separation progress enabling resource redeployment and value creationPortfolio optimization as perpetual value lever with M&A optionalityMargin expansion despite tariff and inflationary headwinds (50-100 bps commitment)Commercial team specialization and execution delivering across all segmentsAI/autonomous coding as competitive differentiator in revenue cycle management

Risks management surfaced:

Tariff headwinds estimated at $100-120 million annuallyInflationary pressures on operating expensesERP cutover risks (U.S./Canada Q3 planned)Foreign exchange volatility (currently a 100 bps benefit)Separation-related timing benefits creating difficult year-over-year comparisons in Q2-Q3

Q&A highlights

Brett Fishman · KeyBank Capital Markets

Requested detail on ERP cutover benefits phasing across segments in Q2, particularly for IPSS and dental, to understand modeling implications.

Management expects over $100 million in advanced orders in Q2, primarily impacting IPSS and dental. These orders are being pulled forward before Q3 US/Canada ERP cutover. Advanced orders will be offset in second half, mostly Q3. This is the last large ERP cutover; company plans to be done with ERPs and 90% of TSAs by year-end. Full year guidance unchanged.

$100 million+ advanced orders expected in Q2Orders primarily impacting IPSS and dental segmentsOrders being pulled from Q3 into Q2 as mitigation strategyUS is the largest region by sales, majority through distribution

Ryan Zimmerman · BTIG

Asked about the 70 basis point impact from order pull forward cited in prepared remarks relative to Asia ERP cutover experience, and what that 70 bps represents.

The 70 basis points of volume in Q1 was related to order advancement for separation activities and SKU exits, not primarily for ERP (since ERP cutovers are Q3). Asia Pacific ERP cutover was successful and in rear-view mirror. The 70 bps represents Q2 volume pulled into Q1 due to registration transitions from 3M to Solventum. Team successfully managed multiple concurrent complexities.

70 basis points of Q1 volume from advance orders (pulled from Q2)Asia Pacific ERP cutover successfully completedMultiple countries including China completed in AsiaPacSeparation activity and registration transitions primary driver of pulls, not ERP

David Roman · Goldman Sachs

Requested breakdown of volume versus mix contribution to growth and color on new product launch impacts year-to-date; followed up on share repurchase program deployment strategy and capital allocation priorities.

Price contribution is approximately flat (±1%), with majority of growth from volume. New product launches feeding enhanced commercial organization; 20 products planned over two years, mostly new products with some relaunches in capacity-constrained areas. Share repurchase program balances anti-dilution with opportunistic buying. Program launched in Q1 and will be balanced with M&A strategy, citing Acera as recent acquisition example.

Price impact: approximately flat ±1%Majority of growth driven by volume~20 new products launching over next two yearsShare repurchase program launched in Q1

Jason Bednar · Piper Sandler

Asked about OPEX savings opportunities from US ERP cutover timing, and whether benefits are wrapped into restructuring cost savings program or separate.

ERP cutovers are not primary objective for cost savings; primary goal is separation from 3M. OpEx does not benefit significantly from ERP cutovers at this time. Transform for the Future program will pick up system benefits, automation, and efficiencies post-separation. Q1 had $740M OpEx (lower in dollars, higher as % of sales) with expected step-down in Q2-Q4 due to seasonal Q1 compensation and timing expenses.

ERP cutovers not designed for near-term OpEx savingsPrimary objective: separation from 3MTransform for the Future program to capture future system efficienciesQ1 OpEx: $740 million (includes seasonal compensation expenses)

Steven Veliket · Mizuho Securities

Asked for approximation of current mix between fully autonomous AI coding and traditional computer-assisted coding (CAC) revenue solutions within HIS segment.

Team confidence increasing on autonomous coding capability; 80-90% of coding could eventually be autonomous (both inpatient and outpatient). Currently in mixed situation with varied adoption across customers. Management expects close to 50% of customers to migrate to autonomous coding during strategic plan period, then expand percentage of autonomous coding used within those hospitals. Benefits include FTE reductions, faster reimbursement, and better revenue capture.

80-90% of coding could eventually be autonomousCurrently in mixed adoption across customersTarget: ~50% of customers migrating to autonomous coding during plan periodCustomers benefit from FTE reductions, faster reimbursement, higher revenue capture

Answers to last quarter's watch list

Whether the +3.0–4.0% ex-SKU FY2026 organic range proves conservative. Q1 reported organic was +2.1%, with ~+3.2% implied ex-SKU — both at the low end of the FY range, and the 180bps tough comp management flagged was real. The print does not yet support sandbagging; if anything, the low-end landing makes the high end of the FY range harder to reach without acceleration in 2H. The Q2 $100M+ pull-forward will distort the next print in both directions.
Continue monitoring
Q1 FY2026 FCF. Q1 FCF came in at -$273M, worse than the FY2025 Q1 cadence and leaving the FY ~$200M guide to be generated entirely from Q2–Q4 (~$473M required). After two consecutive cash misses, this is the third quarter in a row where the cash story is heavier than the rhetoric implies. Management reaffirmed ~$200M but did not detail the 2H cadence in the press release.
Resolved negatively
Tariff impact phasing within FY2026. The press release does not isolate the Q1 tariff realized impact in dollars or basis points. MedSurg margin compression to 13.1% (from Q4's 15.5%) is consistent with the tariff hit landing in the segment most exposed, but the company did not give the clean P&L disclosure that would allow modeling.
Not resolved
HIS organic trajectory. HIS organic was +4.7% in Q1, a modest acceleration from Q4's +3.7% but still short of the "above +5%" bar. The autonomous-coding narrative was quantified for the first time (50% of customers, 80–90% of coding potential). The segment is moving in the right direction; one more quarter of evidence is needed before declaring the recovery in place.
Continue monitoring
Cadence and target sizing of tuck-in M&A. No second tuck-in announced in 1H FY2026 to date. Management escalated the rhetoric to "target-rich environment" but did not disclose deal cadence, average size, or ROIC bar. The share-repurchase launch in Q1 also competes for the same capital, complicating the M&A pacing question.
Continue monitoring
3M raw material supply agreement step-up disclosure. The press release and prepared-remarks excerpts do not mention the 3M raw material supply agreement, the ~100bps FY2027 risk, or the contractual option decision timeline. Management did not address it on the print.
Continue monitoring

What to watch into next quarter

Q2 reported organic print net of the $100M+ pull-forward. $100M against ~$2.16B prior-year Q2 base is roughly 460bps of optical benefit. Watch whether Q2 reported organic prints above +6% (implying the underlying base is tracking at +1.5% or so, weaker than Q1) or above +7% (implying real acceleration). The clean read is reported-minus-pull-forward, not the headline.

Q3 IPSS and Dental segment prints. The pull-forward reversal lands mostly in Q3 and is concentrated in IPSS and Dental. With IPSS already at +0.6% organic in Q1, a Q3 IPSS organic print materially negative — and Dental decelerating sharply from Q1's +3.4% — would be the mechanical consequence. Investors who see those numbers without context will misread them. Management commentary on Q3 framing in Q2 will be the most important guidance disclosure of the year.

2H FCF cadence to reach the ~$200M FY guide. With Q1 at -$273M, the next three quarters need to average +$158M/quarter. The math is doable but not by the prior-year run-rate; watch the Q2 print specifically against a $0–$100M bar.

HIS organic above +5%. Q1's +4.7% is acceleration but still short of the bar. A clean print above +5% in Q2 would corroborate the autonomous-coding adoption-curve narrative; another sub-5% print would push the 50%-of-customers migration target further into the future.

MedSurg operating margin recovery. Q1's 13.1% segment margin is the lowest post-spin print. Watch for a Q2 recovery toward the Q4 15.5% level — anything below 14% would suggest tariffs are sitting more durably in MedSurg than Transform savings can offset.

Second tuck-in M&A announcement and/or buyback pace disclosure. Management's "target-rich environment" rhetoric plus the new buyback program creates capital-allocation tension. Watch for a second announced tuck-in in 1H or specific buyback dollar disclosure in Q2 — silence on both in Q2 would be a soft tell that "perpetual lever" is more rhetoric than pipeline.

Sources

  1. Solventum Q1 FY2026 Form 8-K Exhibit 99.1 (press release) — https://www.sec.gov/Archives/edgar/data/1964738/000196473826000022/q12026-8kerexx991.htm
  2. Solventum Q1 FY2026 earnings call — management prepared remarks and Q&A (extraction-sourced commentary on Q2 pull-forward, Transform for the Future, autonomous coding, and LRP framing)
  3. Solventum Q4 FY2025 Tapebrief (prior-quarter watch list and FY2026 guidance baseline)
  4. Solventum Q3 FY2025 Tapebrief (segment trajectory and FCF context)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.